Key Transaction Details

  • Investment Amount: USD 5 Million.
  • Funding Source: Entirely through internal accruals.
  • Investment Type: Follow-on investment, reinforcing a long-term strategic partnership.
  • Valuation: Described as "attractive".

Strategic Rationale

Management's decision is based on continued confidence in GII's healthcare investment strategy. The company cites compelling long-term growth opportunities in the GCC healthcare sector, supported by:

  • Increasing healthcare expenditure
  • Expanding populations
  • Rising insurance penetration
  • Sustained government investment across the region

About the Investment Platform (GII Healthcare)

  • Assets Under Management: Exceeds USD 3.5 billion.
  • Geographic Presence: Saudi Arabia, UAE, Europe, USA, and India.
  • Current Holdings: Holds a significant equity stake in a prominent healthcare provider based in Saudi Arabia.
  • Track Record: Includes investments in Abeer Medical Company (a leading integrated healthcare provider in Saudi Arabia) and AlMeswak Dental Company (a leading dental and derma care chain in the Kingdom).

Management Commentary

Mr. Aditya Kumar Halwasiya, Chairman & Managing Director, commented that the additional investment demonstrates strong conviction in GII's strategy and the partnership. He stated it reinforces confidence in the quality of the underlying healthcare assets and the long-term value creation potential. The strategic relationship is seen as creating opportunities that extend beyond financial returns, supporting Cupid's mission of enhancing preventive healthcare and wellness outcomes while exploring new geographies.

About Cupid Limited

  • Established: 1993.
  • Business: Leading Indian manufacturer of health and personal care products, including male and female barrier contraceptives, water-based personal care gels, In-Vitro Diagnostic (IVD) kits, and an expanded FMCG portfolio (fragrances, deodorants, toilet sanitizers, hair & body oils, hair removal sprays, face wash).
  • Production Capacity: Recently expanded via a land acquisition in Palava, Maharashtra, increasing capacity by 1.5 times. This will add approximately 770 million male barrier contraceptives and 75 million female barrier contraceptives annually.
  • Certifications: First company globally to attain WHO/UNFPA pre-qualification for both male and female barrier contraceptives.
  • Exports: Products exported to over 125 countries, with a substantial portion of revenue from international markets.
  • Agreements: Has a long-term agreement with WHO/UNFPA.

Disclaimer

The document includes a standard disclaimer noting that forward-looking statements are subject to risks and uncertainties like government actions, economic developments, and technological risks. The company undertakes no obligation to update these statements.